References of "Delanaye, Pierre"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailReference Method and Reference Material Are Necessary Tools to Reveal the Variability of Cystatin C Assays
Bargnoux, Anne-Sophie; Kuster, Nils; Delatour, Vincent et al

in Archives of Pathology & Laboratory Medicine (2016), 140(2), 117-118

Detailed reference viewed: 45 (4 ULg)
Full Text
Peer Reviewed
See detailAdaptation posologique des médicaments et fonction rénale : Quel(s) estimateur(s) faut-il choisir?
DELANAYE, Pierre ULg; Flamant, M; CAVALIER, Etienne ULg et al

in Néphrologie & Thérapeutique (2016), 12(1), 18-31

Le choix de la formule d’estimation du de´ bit de filtration glomérulaire (DFG) a` utiliser pour l’adaptation posologique fait encore de´ bat, principalement entre la formule de Cockcroft et les équations ... [more ▼]

Le choix de la formule d’estimation du de´ bit de filtration glomérulaire (DFG) a` utiliser pour l’adaptation posologique fait encore de´ bat, principalement entre la formule de Cockcroft et les équations plus récentes, MDRD (pour Modified Diet in Renal Disease) et CKD-EPI (pour Chronic Kidney Disease Epidemiology). Les arguments mis en avant en faveur de l’utilisation de la formule de Cockcroft sont : qu’elle a été préférentiellement utilisée pour décider des adaptations posologiques avant la mise sur le marché des médicaments, qu’elle permettrait une meilleure prédiction du risque de survenue des effets indésirables a` l’accumulation des médicaments, qu’elle permettrait de limiter le surdosage médicamenteux chez la personne âgée. Dans cet article d’opinion, nous discutons les faiblesses de l’argumentaire des partisans du maintien de l’utilisation de la formule de Cockcroft dans le contexte de l’adaptation posologique, ainsi que les limites et le manque de fiabilité de cette formule. Nous soutenons la recommandation de la Haute Autorité de sante´ (HAS) sur l’utilisation systématique, en 2015, de l’équation CKD-EPI pour l’estimation du DFG. Lorsque le DFG est e´ value´ dans le but d’adapter la posologie d’un médicament, la désindexation de la surface corporelle est préférable. Compte tenu des difficultés d’estimation du DFG chez la personne âgée et chez les individus a` gabarit hors norme, nous recommandons d’utiliser en priorité dans ces populations, des médicaments pour lesquels un suivi pharmacologique est disponible, ou d’avoir recours à une méthode de référence de mesure du DFG. [less ▲]

Detailed reference viewed: 40 (3 ULg)
See detailAVK en hémodialyse-Rôle, attentes et conséquences cardio vasculaires
DELANAYE, Pierre ULg

Conference given outside the academic context (2016)

Detailed reference viewed: 7 (1 ULg)
Full Text
Peer Reviewed
See detailManaging Chronic Kidney Disease in Older People--Reply
Glassock, rj; DELANAYE, Pierre ULg; El-Nahas, M

in JAMA : Journal of the American Medical Association (2016), 315(3),

Detailed reference viewed: 4 (1 ULg)
Full Text
Peer Reviewed
See detailSerum calcitriol concentrations measured with a new direct automated assay in a large population of adult healthy subjects and in various clinical situations
Souberbielle, JC; CAVALIER, Etienne ULg; DELANAYE, Pierre ULg et al

in Clinica Chimica Acta (2015), 451 (Pt B)

The measurement of calcitriol [1,25(OH2)D], is important for the differential diagnosis of several disorders of calcium/phosphorus metabolism but is time-consuming and tricky. We measured serum calcitriol ... [more ▼]

The measurement of calcitriol [1,25(OH2)D], is important for the differential diagnosis of several disorders of calcium/phosphorus metabolism but is time-consuming and tricky. We measured serum calcitriol with a new automated direct assay on the Liaison XL platform in 888 healthy French Caucasian subjects aged 18–89 years, 32 patients with a surgically-proven PHPT, 32 pregnant women at the end of the first and at the end of the third trimester, and 24 dialysis patients before and after one year of supplementationwith vitamin D3 or placebo. The mean calcitriol concentration (±SD) in the healthy population was 52.9 ± 14.5 ng/L with a 95% CI interval of 29–83.6 ng/L. In PHPT patients, calcitriol concentration was 81.6±29.0 ng/L, 15 of them (46.9%) having a concentration N83.6 ng/L. In pregnant women, calcitriol was 80.4 ± 26.4 ng/L at the end of the first trimester, and 113.1±33.0 ng/L at the end of the third trimester, 12 (37.5%) and 26 (81.3%) of them having a calcitriol concentration N83.6 ng/L at the first and third trimesters respectively. In 14 dialysis patients, calcitriol was 9.5±7.7 ng/L and rose to 19.3 ng/L after one year of supplementation with 50,000 IU vitamin D3/month. In 10 other dialysis patients, calcitriol was 9.9±2.9 ng/L and remained stable (12.4±3.7 ng/L) after one year of placebo. In conclusion, this new automated calcitriol assay, in addition to presenting excellent analytical performances, gives the expected variations in patients compared to “normal” values obtained in an extensive reference population [less ▲]

Detailed reference viewed: 21 (4 ULg)
Full Text
Peer Reviewed
See detailConsiderations in parathyroid hormone testing.
Cavalier, Etienne ULg; Plebani, Mario; DELANAYE, Pierre ULg et al

in Clinical Chemistry & Laboratory Medicine (2015), 53(12), 1913-9

Parathyroid hormone (PTH) is a major player in phosphocalcic metabolism and its measurement is very important for the correct diagnosis and treatment of several diseases. PTH determination represents the ... [more ▼]

Parathyroid hormone (PTH) is a major player in phosphocalcic metabolism and its measurement is very important for the correct diagnosis and treatment of several diseases. PTH determination represents the paradigm of quality in laboratory medicine as many variables in the pre-, intra-, and post-analytical phases strongly affect the value of the clinical information. Analytical determination of PTH has been rendered difficult by the presence, in the circulation, of truncated fragments that can cross-react with the antibodies used for its determination. In addition, pre-analytical phase is complicated by the lack of stability of the peptide and the best sample to use for its determination remains controversial, as well as sample handling and storage. PTH secretion is also affected by circadian and seasonal rhythms and by physical exercise. Finally, from the post-analytical perspective, establishment of reliable reference ranges requires further efforts as the selection criteria for reference subjects should take into consideration new variables such as gender, race and vitamin D levels. Finally, clinical guidelines have recently revised and improved the criteria for a correct interpretation of PTH values. [less ▲]

Detailed reference viewed: 11 (0 ULg)
Full Text
Peer Reviewed
See detailL'éveil de la matrix-gla-protéine sonnera le glas des calcifications vasculaires
DELANAYE, Pierre ULg; Liabeuf, Sophie; BOUQUEGNEAU, Antoine ULg et al

in Néphrologie & Thérapeutique (2015), 11(4), 191-200

La matrix-gla-protéine (MGP) est principalement sécrétée par les chondrocytes et les cellules musculaires lisses des parois vasculaires. Son rôle est d’inhiber localement le développement des ... [more ▼]

La matrix-gla-protéine (MGP) est principalement sécrétée par les chondrocytes et les cellules musculaires lisses des parois vasculaires. Son rôle est d’inhiber localement le développement des calcifications vasculaires. MGP doit bénéficier de deux processus post-transcriptionnels avant d’être pleinement active : une phosphorylation de résidus sérine et une carboxylation de résidus glutamate. Cette carboxylation ne peut se faire qu’en présence de quantité suffisante de vitamine K. Plusieurs formes de MGP circulent donc dans le plasma, certaines étant totalement inactives (la MGP déphosphorylée et décarboxylée), d’autres possédant une activité biologique variable en fonction du nombre de sites carboxylés ou phosphorylés. Il existe un lien théorique étroit entre MGP, vitamine K, calcifications vasculaires et maladies cardiovasculaires et ce, particulièrement chez les patients souffrant d’insuffisance rénale chronique, a fortiori s’ils sont dialysés. Si l’existence de ce lien a été démontrée via de nombreuses et solides données fondamentales, les données cliniques restent, à ce jour, observationnelles et doivent donc être interprétées avec prudence. Mesurer une fraction de MGP dans le plasma pour estimer le degré de calcification d’un patient donné n’est pas encore d’actualité . La forme inactive pourrait être utile pour juger des réserves en vitamine K au niveau vasculaire. Dans cet article de revue, nous reviendrons sur les bases théoriques du rôle de MGP dans le processus de calcification vasculaire, sur le défi analytique que représente sa détermination dans le plasma, ainsi que sur les liens entre MGP, vitamine K et calcifications vasculaires en population géne´ rale et chez les patients insuffisants rénaux. [less ▲]

Detailed reference viewed: 42 (4 ULg)
Full Text
Peer Reviewed
See detailInhibiteurs des calcifications cardiovasculaires.
Liabeuf, Sophie; DELANAYE, Pierre ULg; Cavalier, Etienne ULg et al

in Annales de Biologie Clinique (2015), 73(3), 315-22

Vascular calcification is a marker of cardiovascular risk increase. Age and specific disease such as diabetes or chronic kidney disease are important factors for calcification genesis. Vascular ... [more ▼]

Vascular calcification is a marker of cardiovascular risk increase. Age and specific disease such as diabetes or chronic kidney disease are important factors for calcification genesis. Vascular calcification process is a complex phenomenon, involving several activators and inhibitors factors. Indeed, recent works related to in vitro and in vivo experimental studies have led to a better understanding of calcification process and identification of molecules able to modulate this system. This revue will summarize some of these molecules with a particular interest of those with therapeutic relevance. We will present: i) calcium sensing receptor and its modulation by cinacalcet; ii) pyrophosphate supplementation; iii) fetuin A and overall propensity serum test for calcification and finally; iv) matrix-Gla-protein and the use of vitamin K to prevent vascular calcification progression. [less ▲]

Detailed reference viewed: 12 (0 ULg)
Full Text
Peer Reviewed
See detailLa sclérostine: un nouveau biomarqueur d'intérêt en néprhologie
Pelletier; Jean, Guillaume; Fouque, Denis et al

in Annales de Biologie Clinique (2015), 73(3), 305-13

Sclerostin is an osteocyte-specific glycoprotein secreted by the osteocyte and involved in the regulation of bone mass. High sclerostin levels are associated with osteoporosis, whereas low sclerostin ... [more ▼]

Sclerostin is an osteocyte-specific glycoprotein secreted by the osteocyte and involved in the regulation of bone mass. High sclerostin levels are associated with osteoporosis, whereas low sclerostin levels are correlated with higher bone mineral density. It seems interesting to investigate a potential association between sclerostin levels and vascular calcifications since sclerostin is considered as a potent inhibitor of bone formation. In chronic kidney disease, serum sclerostin levels rise as renal function declines. Preliminary studies show a positive association between serum sclerostin and vascular calcification, but the link between sclerostin and survival of patients remains unclear in the absence of large-scale studies. [less ▲]

Detailed reference viewed: 16 (1 ULg)
Full Text
Peer Reviewed
See detailProblems with the PTH assays
CAVALIER, Etienne ULg; DELANAYE, Pierre ULg; Nyssen, Laurent ULg et al

in Annales d'Endocrinologie (2015), 76(2), 128-133

Even if the first assay for parathyroid hormone (PTH) was published in the early 1960s, its determination remains a challenge even today. Indeed, in the circulation, PTH is present in its active form (PTH ... [more ▼]

Even if the first assay for parathyroid hormone (PTH) was published in the early 1960s, its determination remains a challenge even today. Indeed, in the circulation, PTH is present in its active form (PTH 1-84), but many PTH fragments can also be present. These fragments accumulate when renal function declines and are recognized, at different extents, by the 2nd generation ("intact") PTH assays that are widely used in the clinical laboratories. Some assays, called "3rd generation PTH" do not recognize these fragments, but are not available everywhere. Hence, different problems are also linked with PTH determination. Among them, one can cite the lack of a reference method, the lack of standardization of the assays and, sometimes, the lack of consistent reference range. We can also point out stability problems and a large intra-individual variation. A workgroup is working on these problems under the auspices of the IFCC and we hope that some of these problems will be resolved in the next years. In this article, we will discuss all the possible issues of PTH determination. [less ▲]

Detailed reference viewed: 20 (9 ULg)
Full Text
Peer Reviewed
See detailBiomarkers and physiolpathology in the cardiorenal syndrome
BOUQUEGNEAU, Antoine ULg; KRZESINSKI, Jean-Marie ULg; DELANAYE, Pierre ULg et al

in Clinica Chimica Acta (2015), 443

Acute cardiorenal syndrome (CRS) corresponds to an association of acute heart failure and a worsening of renal function. The detection of acute kidney injury (AKI) unfortunately occurs at a late stage of ... [more ▼]

Acute cardiorenal syndrome (CRS) corresponds to an association of acute heart failure and a worsening of renal function. The detection of acute kidney injury (AKI) unfortunately occurs at a late stage of CRS, leading to an increased mortality of the patients. In this review, we described the pathophysiology of CRS and discussed the potential interest of biochemical biomarkers (namely creatinine, cystatin C, NGAL, KIM-1, fatty acid binding protein, Nacetyl-β-D-glucosaminidase and IL-18) that could potentially help to detect AKI earlier and thus reduce the morbi-mortality of the patients suffering from CRS. [less ▲]

Detailed reference viewed: 38 (11 ULg)
Full Text
Peer Reviewed
See detailPlace de la vitamine D native en dialyse
DELANAYE, Pierre ULg; BOUQUEGNEAU, Antoine ULg; KRZESINSKI, Jean-Marie ULg et al

in Néphrologie & Thérapeutique (2015), 11(1), 5-15

Chronic kidney disease is frequent and usually responsible of mineral and bone disorder. These abnormalities lead to increased morbidity and mortality. To become active, native vitamin D needs a first ... [more ▼]

Chronic kidney disease is frequent and usually responsible of mineral and bone disorder. These abnormalities lead to increased morbidity and mortality. To become active, native vitamin D needs a first hydroxylation in the liver, and a second one in the kidney. Next to its action on bone metabolism, vitamin D also possesses pleiotropic actions on cardiovascular, immune and neurological systems as well as antineoplastic activities. End-stage renal disease (ESRD) is also associated with a decrease in vitamin D activity by mechanisms including the increase of plasma phosphate concentration, secretion of FGF- 23 and decrease in 1a-hydroxylase activity. The prevalence of 25 hydroxy-vitamin D deficiency depends on the chosen cut-off value to define this lack. Currently it is well established that a patient has to be substituted when 25 hydroxy-vitamin D level is under 30 ng/mL. The use and monitoring of 1.25 hydroxy-vitamin D is still not recommended in routine practice. The goals of vitamin D treatment in case of ESRD are to substitute the deficiency and to prevent or treat hyperparathyroidism. Interest of native vitamin D in first intention is now well demonstrated. This review article describes the vitamin D metabolism and physiology and also the treatment for vitamin D deficiency in ESRD population. [less ▲]

Detailed reference viewed: 21 (9 ULg)
Full Text
Peer Reviewed
See detailVascular calcification: from pathophysiology to biomarkers
EVRARD, Séverine ULg; DELANAYE, Pierre ULg; Kamel, S et al

in Clinica Chimica Acta (2015), 438

The link between vascular calcification (VC) and increased mortality is now well established. Over time, as clinical importance of this phenomenon has begun to be fully considered, scientists have ... [more ▼]

The link between vascular calcification (VC) and increased mortality is now well established. Over time, as clinical importance of this phenomenon has begun to be fully considered, scientists have highlightedmore and more physiopathological mechanisms and signaling pathways that underlie VC. Several conditions such as diabetes, dyslipidemia and renal diseases are undoubtedly identified as predisposing factors. But even if the process is better understood,many questions still remain unanswered. This reviewbriefly develops the various theories that attempt to explain mineralization genesis. Nonetheless, the main purpose of the article is to provide a profile of the various existing biomarkers of VC. Indeed, in the past years, a lot of inhibitors and promoters, which form a dense and interconnected network, were identified. Given importance to assess and control mineralization process, a focusing on accumulated knowledge of each marker seemed to be necessary. Therefore, we tried to define their respective role in the physiopathology and how they can contribute to calcification risk assessment. Among these, Klotho/fibroblast growth factor-23, fetuin-A, Matrix Gla protein, Bone morphogenetic protein-2, osteoprotegerin, osteopontin, osteonectin, osteocalcin, pyrophosphate and sclerostin are specifically discussed. [less ▲]

Detailed reference viewed: 42 (4 ULg)
Full Text
Peer Reviewed
See detailimpact of stopping vitamin K antagonist therapy on concentrations of dephospho-uncarboxylated Matrix Gla protein
DELANAYE, Pierre ULg; DUBOIS, Bernard ULg; LUKAS, Pierre ULg et al

in Clinical Chemistry & Laboratory Medicine (2015), 53(8), 191-193

Detailed reference viewed: 31 (9 ULg)